Page last updated: 2024-12-07

imiphos

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Imiphos (also known as 3-amino-1-hydroxypropylidene-1,1-bisphosphonate) is an organic compound with the chemical formula C3H10N2O7P2. It is a bisphosphonate, a class of drugs that are used to treat bone diseases. Imiphos is a potent inhibitor of osteoclast activity, which is the process by which bone is broken down. It is also a potent inhibitor of bone resorption, which is the loss of bone tissue. Imiphos is being studied for its potential to treat a variety of bone diseases, including osteoporosis, Paget's disease, and bone cancer. It is also being studied for its potential to prevent bone loss in patients who are at risk for osteoporosis, such as postmenopausal women and patients who are receiving long-term corticosteroid therapy. Imiphos is currently in clinical trials. Imiphos is synthesized through a multi-step process that involves the reaction of a phosphorus-containing compound with an amine.'

imiphos: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID101962
CHEMBL ID507092
SCHEMBL ID10751725
MeSH IDM0042204

Synonyms (18)

Synonym
1078-79-1
3-(bis(1-aziridinyl)phosphinyl)-2-methylthiazolidine
imiphos
marcophane
phosphine oxide, bis(1-aziridinyl)(2-methyl-3-thiazolidinyl)-
markofane
brn 1214283
marcophan
CHEMBL507092
3-[bis(aziridin-1-yl)phosphoryl]-2-methyl-1,3-thiazolidine
unii-83tb06md0k
83tb06md0k ,
SCHEMBL10751725
imifos
thiazolidine, 3-(bis(1-aziridinyl)phosphinyl)-2-methyl-
ie-35
DTXSID10910525
Q27269448
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID432900Toxicity in rat bearing M1 cells assessed as mortality at 40% LD50 per day2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Aziridine alkaloids as potential therapeutic agents.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]